Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bachem Holding AG ( (CH:BANB) ) just unveiled an announcement.
Bachem Holding AG reported a strong financial performance in the first half of 2025, with group sales reaching CHF 313.0 million, marking a 30.2% increase compared to the previous year. The company also saw a significant rise in EBITDA to CHF 91.0 million, reflecting a 64.0% increase. Bachem is investing heavily in expanding its production capacity, with more than CHF 400 million planned for 2025, and aims for over CHF 1 billion in revenue by 2026. The expansion includes the development of a new production site in Sisslerfeld, Switzerland, and the continued enhancement of existing facilities. These strategic moves are expected to bolster Bachem’s market position and meet the growing demand for its products.
The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
More about Bachem Holding AG
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With a comprehensive service offering, Bachem provides pharmaceutical and biotechnology companies worldwide with products for research, clinical development, and commercial application. Headquartered in Switzerland, with locations in Europe, the USA, and Asia, Bachem operates internationally and has more than 50 years of experience and industry-leading expertise. The company is listed on the SIX Swiss Exchange.
Average Trading Volume: 115,862
Technical Sentiment Signal: Sell
Current Market Cap: CHF4.21B
For a thorough assessment of BANB stock, go to TipRanks’ Stock Analysis page.